We are live on ! Find out more
PTHS

Pelthos Therapeutics
PTHS

15 hedge funds and large institutions have $27.9M invested in Pelthos Therapeutics in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more capital invested

Capital invested by funds: $13M → $27.9M (+$14.9M)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

13.93% more ownership

Funds ownership: 15.21% → 29.14% (+14%)

7% more funds holding

Funds holding: 14 → 15 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.18%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
4
Increased
10
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$5.58M
2
JGC
J. Goldman & Co
New York
+$2.25M
3
BFM
Boothbay Fund Management
New York
+$1.71M
4
CF
Cantor Fitzgerald
New York
+$1.01M
5
DP
Diadema Partners
New Jersey
+$418K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$23.2K
2
Citigroup
Citigroup
New York
-$28
3
JP Morgan Chase
JP Morgan Chase
New York
-$28
Name Holding Trade Value Shares
Change 		Change in
Stake
M
1
Murchinson
Ontario, Canada
$8.97M +$273K +9,479 +3%
IC
2
Ikarian Capital
Texas
$7.93M +$5.58M +193,307 +310%
BFM
3
Boothbay Fund Management
New York
$2.5M +$1.71M +59,435 +280%
JGC
4
J. Goldman & Co
New York
$2.42M +$2.25M +78,006 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.33M +$236K +8,184 +12%
CF
6
Cantor Fitzgerald
New York
$1.08M +$1.01M +34,990 New
DP
7
Diadema Partners
New Jersey
$775K +$418K +14,502 +138%
DMKJ
8
David M. Knott Jr
$598K +$380K +13,169 +215%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$422K +$95K +3,295 +32%
Millennium Management
10
Millennium Management
New York
$343K +$319K +11,057 New
PFCS
11
Pale Fire Capital SE
Czech Republic
$251K +$234K +8,100 New
PAP
12
Persistent Asset Partners
Hong Kong
$186K +$104K +3,604 +150%
SPIA
13
Steward Partners Investment Advisory
New York
$59.2K – – –
UBS Group
14
UBS Group
Switzerland
$13.5K +$8.57K +297 +217%
Bank of America
15
Bank of America
North Carolina
$372 +$29 +1 +9%
TRCT
16
Tower Research Capital (TRC)
New York
– -$23.2K -827 Closed
Citigroup
17
Citigroup
New York
– -$28 -1 Closed
JP Morgan Chase
18
JP Morgan Chase
New York
– -$28 -1 Closed

PTHS Hedge Fund Activity: Q4 2025 in Review

15 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q4 2025, worth a combined $27.9M — up 115% from $13M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new PTHS positions and 3 closed out — a net gain of 1 holder — while 10 added to existing stakes and 0 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $5.58M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $23.2K sold.

  • 15 institutional investors held Pelthos Therapeutics (PTHS) as of Q4 2025, up from 14 in Q3 2025.
  • Funds reported $27.9M of Pelthos Therapeutics stock for Q4 2025, up 115% quarter-over-quarter.
  • 4 funds opened new Pelthos Therapeutics positions in Q4 2025 and 3 closed out, a net change of +1 holder.
  • The largest Pelthos Therapeutics buyer in Q4 2025 was Ikarian Capital, an estimated $5.58M added.
  • The largest Pelthos Therapeutics seller in Q4 2025 was Tower Research Capital (TRC), an estimated $23.2K sold.

Based on aggregated 13F filings for Q4 2025.